Skip To Main Content

Search

For optimal search results, please limit to 2 product keywords

If you are searching for information related to a product:

  • For optimal results, please enter at least 2 search terms in addition to product name
  • Example: [product name] [search term] [search term]
  • Example: Product + clinical trials
  • For an exact match, please include search terms in double quotations. For example: "Elevatum"

    Please enter search terms.

    Mosunetuzumab

    Other names: RG7828; RO7030816

    Modality: T-cell engaging bispecific antibody

    Disease State: Systemic Lupus Erythematosus (SLE)

    Summary

    Mosunetuzumab is a humanized full-length T cell engaging bispecific antibody designed to target both cluster of differentiation (CD) 20 (CD20) on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to engage and eliminate B cells.1

    Clinical Trials

    Mosunetuzumab
    NCT ID Study Phase Enrollment Status Study Title
    NCT07598396 Phase II Recruiting A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis View details

    Proposed Mechanism of Action

    Mosunetuzumab is an investigational full length, humanized, IgG1 bispecific antibody that targets both CD3 and CD20.  

    Anti-CD20/anti-CD3 bispecifics are proposed to create an immunological synapse between T cells and target B cells.2,3

    Concomitant binding to CD3 and CD20

    The bispecific concomitantly binds to CD3ε, a component of the TCR complex on the surface of T cells, and to CD20 on the surface of B cells.2,3

    Synapse formation

    Engagement of both arms of the bispecific (binding to CD3ε and CD20) results in crosslinking of the TCR and formation of an immunologic synapse. T cells are then activated leading to B-cell killing, cytokine release and T-cell proliferation.4

    1. Budde LE, Sehn LH, Matasar M, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055-1065. doi:10.1016/​S1470-2045(22)00335-7
    2. Ferl GZ, Reyes A, Sun LL, et al. A Preclinical Population Pharmacokinetic Model for Anti-CD20/CD3 T-Cell-Dependent Bispecific Antibodies. Clin Transl Sci. 2018;11(3):296-304. doi:10.1111/​cts.12535
    3. Sun LL, Ellerman D, Mathieu M, et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015;7(287):287ra70. doi:10.1126/​scitranslmed.aaa4802
    4. Dieckmann NM, Frazer GL, Asano Y, Stinchcombe JC, Griffiths GM. The cytotoxic T lymphocyte immune synapse at a glance. J Cell Sci. 2016;129(15):2881-2886. doi:10.1242/​jcs.186205

    Looking for more information?

    Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.

    Connect with an MSL
    Submit a Request

    Call the Trial Information Support Team: 1-888-662-6728 Hours: Monday-Friday, 5am-5pm PT

    TOP

    • CD
      cluster of differentiation

    • IgG1
      immunoglobulin G1

    • SLE
      Systemic Lupus Erythematosus

    • TCR
      T-cell receptor

    +